1. A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. Issue 10 (November 2016) Authors: Ren, Yan; Wang, Maria; Couto, Suzana; Hansel, Donna E.; Miller, Karen; Lopez-Girona, Antonia; Bjorklund, Chad C.; Gandhi, Anita K.; Thakurta, Anjan; Chopra, Rajesh; Breider, Michael Journal: Applied immunohistochemistry & molecular morphology Issue: Volume 24:Issue 10(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Issue 9 (28th July 2020) Authors: Van Oekelen, Oliver; Parekh, Samir; Cho, Hearn J.; Vishnuvardhan, Nivetha; Madduri, Deepu; Richter, Joshua; Ip, Chun; Lau, Kenneth; Florendo, Erika; Mancia, Ines S.; Thomas, Joanne; Verina, Daniel; Chan, Elaine; Zarychta, Katarzyna; La, Lisa; Strumolo, Gina; Melnekoff, David T.; Leshchenko, Viole... Journal: Leukemia & lymphoma Issue: Volume 61:Issue 9(2020) Page Start: 2208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity. (2nd August 2017) Authors: Hagner, Patrick R.; Chiu, Hsiling; Ortiz, Maria; Apollonio, Benedetta; Wang, Maria; Couto, Suzana; Waldman, Michelle F.; Flynt, Erin; Ramsay, Alan G.; Trotter, Matthew; Gandhi, Anita K.; Chopra, Rajesh; Thakurta, Anjan Journal: British journal of haematology Issue: Volume 179:Number 3(2017) Page Start: 399 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Issue 6 (17th October 2019) Authors: Lalezari, Shadan; Reding, Mark T.; Pabinger, Ingrid; Holme, Pal Andre; Negrier, Claude; Chalasani, Pavani; Shin, Ho‐Jin; Wang, Maria; Tseneklidou‐Stoeter, Despina; Maas Enriquez, Monika Journal: Haemophilia Issue: Volume 25:Issue 6(2019) Page Start: 1011 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Issue 12 (15th October 2021) Authors: Kalff, Anna; Khong, Tiffany; Ramachandran, Malarmathy; Walker, Patricia; Schwarer, Anthony; Roberts, Andrew W.; Campbell, Philip; Filshie, Robin; Norton, Sam; Reynolds, John; Young, Mary; Pierceall, William; Thakurta, Anjan; Guo, Manman; Oppermann, Udo; Wang, Maria; Ren, Yan; Kennedy, Nola; Parek... Journal: Leukemia & lymphoma Issue: Volume 62:Issue 12(2021) Page Start: 2981 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Issue 3 (5th April 2021) Authors: Reding, Mark T.; Pabinger, Ingrid; Holme, Pal Andre; Poulsen, Lone; Negrier, Claude; Chalasani, Pavani; Maas Enriquez, Monika; Wang, Maria; Meijer, Karina; Mancuso, Maria Elisa; Lalezari, Shadan Journal: Haemophilia Issue: Volume 27:Issue 3(2021) Page Start: e347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression. (18th December 2012) Authors: Zhang, Ling‐Hua; Kosek, Jolanta; Wang, Maria; Heise, Carla; Schafer, Peter H.; Chopra, Rajesh Journal: British journal of haematology Issue: Volume 160:Number 4(2013:Feb.) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. (October 2014) Authors: Bookhart, Brahim K.; Haskell, Lloyd; Bamber, Luke; Wang, Maria; Schein, Jeff; Mody, Samir H. Journal: Journal of medical economics Issue: Volume 17:Number 10(2014) Page Start: 691 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. (28th October 2013) Authors: Gandhi, Anita K.; Mendy, Derek; Waldman, Michelle; Chen, Gengxin; Rychak, Emily; Miller, Karen; Gaidarova, Svetlana; Ren, Yan; Wang, Maria; Breider, Michael; Carmel, Gilles; Mahmoudi, Afshin; Jackson, Pilgrim; Abbasian, Mahan; Cathers, Brian E.; Schafer, Peter H.; Daniel, Tom O.; Lopez‐Girona, An... Journal: British journal of haematology Issue: Volume 164:Number 2(2014:Jan.) Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Issue 9 (29th July 2019) Authors: Kalff, Anna; Khong, Tiffany; Mithraprabhu, Sridurga; Bergin, Krystal; Reynolds, John; Bowen, Kathryn M.; Thakurta, Anjan; Guzman, Roberto; Wang, Maria; Couto, Suzana; Ren, Yan; Spencer, Andrew Journal: Leukemia & lymphoma Issue: Volume 60:Issue 9(2019) Page Start: 2143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗